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Abstract
Background: People with end-stage kidney disease have an increased risk of active tuberculosis (TB). Previous
systematic reviews have demonstrated that patients with chronic kidney disease (CKD) have increased risk of severe
community-acquired infections. We investigated the association between CKD (prior to renal replacement therapy)
and incidence of TB in UK General Practice.
Methods: Using the UK Clinical Practice Research Datalink, 242,349 patients with CKD (stages 3-5) (estimated glomerular
filtration rate < 60mL/min/1.73m2 for ≥3months) between April 2004 and March 2014 were identified and individually
matched (by age, gender, general practice and calendar time) to a control from the general population without known CKD.
The association between CKD (overall and by stage) and incident TB was investigated using a Poisson regression analysis
adjusted for age, gender, ethnicity, socio-economic status, chronic obstructive pulmonary disease (COPD) and diabetes.
Results: The incidence of TB was higher amongst patients with CKD compared to those without CKD: 14.63 and 9.89 cases
per 100,000 person-years. After adjusting for age, gender, ethnicity, socio-economic status, diabetes and COPD, the association
between CKD and TB remained (adjusted rate ratio [RR] 1.42, 95% confidence interval [CI] 1.01–1.85). The association may be
stronger amongst those from non-white ethnic minorities (adjusted RR 2.83, 95%CI 1.32–6.03, p-value for interaction with
ethnicity = 0.061). Amongst those with CKD stages 3–5, there was no evidence of a trend with CKD severity.
Conclusions: CKD is associated with an increased risk of TB diagnosis in a UK General Practice cohort. This group of patients
should be considered for testing and treating for latent TB.
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Background
Chronic kidney disease (CKD) is recognised as a growing
public health problem [1]. CKD stages 3–5 (defined as
estimated glomerular filtration rate [eGFR] < 60mL/
min/1.73 m2 for ≥3 months) are estimated to affect ap-
proximately 6% of the general population in England [2].
CKD can progress to end-stage kidney disease (ESKD)
requiring renal replacement therapy (RRT) in a small
but substantial proportion of people [3]. CKD is associ-
ated with a range of comorbidities and increased risk of
infection and is classed as an independent risk factor for
active tuberculosis (TB) [3–6].
Tuberculosis (TB) disease is a global public health
problem with imperfect control options [7]. In England,
despite a low TB burden setting and a reduction in over-
all TB cases in recent years, the proportion of TB cases
with at least one risk factor (homelessness, drug or alco-
hol misuse or imprisonment) has increased in the last
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year [8]. The burden of disease is concentrated in large
urban areas with London having the highest TB inci-
dence of any western European capital [8, 9]. There is
evidence that a large number of new TB diagnoses in
the UK come from activation of latent TB [9]. The re-
cent decline of overall TB incidence in England has been
attributed partly to the impact of testing and treating pa-
tients with latent TB, the UK TB pre-entry screening
programme and improvements in TB control [8]. Efforts
to further identify, access, screen and treat those at high
risk of TB are in order to achieve year on year reduc-
tions in TB. A systematic review in 2015 found evidence
of an increased risk of active TB in patients with ESKD
compared to the general population [10]. However, none
of these studies were based in the UK nor adjusted for
comorbidities or lifestyle factors. Specifically, the review
was unable to explore the influence of diabetes and
other known TB risk factors with the data and so could
not assess the extent of confounding by these. A recent
cohort study in a population in Taiwan suggested an in-
creased risk of TB in early stages of CKD [11]. However,
the background incidence of TB in this population is far
higher than that of the UK.
We used a large representative primary care database
to compare the rates of incident TB in those with and
without CKD stages 3–5, excluding those on RRT and
assessed the dose-response relationship between CKD
stages and TB incidence. We also explored whether the
CKD-TB association varied with age and ethnic group.
Methods
Data sources
In the UK, the primary care system acts as a gatekeeper
to healthcare-patients (excluding those in prisons, mili-
tary service and the homeless) need to be registered with
a primary care doctor to access National Health Service
(NHS) nonemergency care. The Clinical Practice Re-
search Datalink (CPRD) is an ongoing primary care
database of routinely recorded primary care electronic
data. Diseases can be identified using diagnostic Read
codes in the data. Over 650 general practices contrib-
uted data meeting quality control standards to the
CPRD, covering and representing (with respect to age,
sex and ethnicity) nearly 7% of the UK population [12].
We used CPRD linked to the inpatient Hospital Episodes
Statistics (HES) for more accurate and complete infor-
mation of ethnicity [13] which is available for approxi-
mately 75% of participating general practices in England.
Data were also linked to the Office of National statistics
(ONS) data for mortality information and to the Index
of Multiple Deprivation (IMD) in quintiles as assigned
by postcode of residence [14]. Ethical approval for this
study was obtained from the Independent Scientific Ad-
visory Committee (ISAC), which oversees research
involving de-identified CPRD data (Protocol 17_124R) as
well as from the LSHTM Research Ethics Committee
(reference: 14162).
Study population
All living adults (> 18 years) contributing to HES-linked
CPRD anytime from 1 April 2004 to 31 March 2014
were eligible for inclusion. We excluded patients already
receiving RRT (haemodialysis, peritoneal dialysis, and
kidney transplantation) prior to cohort entry (Add-
itional file 1). Patients were eligible for inclusion at the
latest of: the date that the practice reached CPRD quality
control standards or 1 year after practice registration
[15] or 1 April 2004 (testing for CKD was incentivised in
2004 for those with diabetes and in 2006 for those at risk
of CKD). Follow-up continued until the incidence of TB
diagnosis, death, incidence of RRT, change of practice,
last data collection from the practice or 31/03/2014 (end
date of HES version 10 linkage eligibility).
Definition of exposure and outcome
During the study period, CKD was classified into 5
stages using eGFR and markers of kidney damage.
Markers of kidney damage include a urinary albumin:
creatinine ratio greater than 3mg/mmol, urine sediment
abnormalities and others are listed in the National Insti-
tute of Care and Excellence (NICE) Guidelines [3]. CKD
stages 3–5 status was defined in patients based on two
consecutive measurements of eGFR < 60 mL/min/
1.73m2 taken more than 3 months apart [16]. Patients,
including those who had CKD stages 3–5 before April
2004, were included in the cohort on the date when they
first satisfied the CKD stages 3–5 definition (i.e. second
eGFR < 60 ml/min/1.73m2) during the eligibility period
as previously defined [17]. As a comparison group, pa-
tients without known CKD stages 3–5 (with or without
creatinine measurement) were selected randomly from
the same practice population, matched on age, sex, and
calendar time (i.e. index date). Identification and man-
agement of CKD and other chronic diseases are ex-
pected to depend on GP and calendar time [18, 19].
Each control entered the cohort on the same date as
their CKD stages 3–5 counterpart. Controls who devel-
oped CKD stages 3–5 (i.e. second eGFR < 60ml/min/
1.73m2 more than 3 months after the first measure) later
were censored at the time of satisfying CKD defin-
ition and contributed separately as an incident patient
with CKD stages 3–5 from that point forward with
their own matched control. In a subgroup analysis
amongst those with CKD, patients were classified with
different stage of CKD at baseline: CKD stage 3a
(eGFR 45–59 mL/min/1.73m2), CKD stage 3b (eGFR
30–44 mL/min/1.73m2), and CKD stage 4 or 5 (eGFR
< 30 mL/min/1.73m2).
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TB diagnosis was based on a list of TB diagnosis codes
as developed in a previous study [20]. We excluded pa-
tients with a history of TB diagnosis at cohort entry
(Fig. 1). Incident TB was defined as a recorded TB diag-
nosis for the first time in CPRD after the cohort entry
(i.e. the date of satisfying CKD definition for CKD stages
3–5 patients and the same date for matched controls).
By assuming that GPs record a previous TB diagnosis
before GP registration within a certain period of time
after GP registration (1 year), the first recorded diagnosis
(after 1 year from GP registration) of TB is regarded as a
new TB experience in his/her life.
Covariates
People at risk of TB infection and disease are those
who are close contacts with an infectious TB case,
immunocompromised, healthcare workers, without a
BCG vaccination, live in/come from a high TB preva-
lent country, are very young or old and from under-
served groups. Those with silicosis, on chemotherapy,
with excessive alcohol use, or those with diabetes
may be more likely to develop TB [6]. We used eth-
nicity, age, IMD as a proxy for socio-economic status,
gender, body mass index (BMI), smoking and chronic
illnesses such as diabetes, cancer and chronic ob-
structive pulmonary disease (COPD) and rheumatoid
arthritis to approximate/measure these factors [21–25].
Risk factors associated with CKD progression include, car-
diovascular disease, age, proteinuria, acute kidney injury,
hypertension, diabetes, smoking, African, African-
Caribbean or Asian family origin, chronic use of nonste-
roidal anti-inflammatory drugs (NSAIDs) and untreated
urinary outflow tract obstruction [26]. Hypertension
was considered to be on the causal pathway as it is
also an outcome of worse kidney function [27]. Previ-
ous literature shows that low SES, high BMI, persist-
ent asthma, cancer, COPD and rheumatoid arthritis
are risk factors for CKD [28–33]. Factors that were
risk factors for TB and were associated with CKD
were treated as potential confounders.
Based on previous studies using UK primary care
data, we classified patients with no record of ethnicity
as white [34, 35]. Age and financial year were ana-
lysed as categorical variables, with groups < 55, 55–
64, 65–74, 75–84,> = 85 and from 1 April to 31
March for every 2 years respectively. Chronic diseases
Fig. 1 Flow chart of the selection of matched patients with and without chronic kidney disease stages 3–5. CKD = chronic kidney disease stages
3–5, CPRD = clinical practice research datalink, HES = hospital episode statistics, RRT = renal placement therapy. *Matched control randomly
selected individuals without CKD. 41,151 patients censored from control group after developing CKD. They were included in CKD cohort from
that point forward
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were recorded as binary variables (i.e. presence or absence
of each condition at the time of cohort entry). Socio-
economic status was allocated at an individual-level by
quintile using 2010 ONS estimates of the IMD (composite
area-level marker of deprivation) [36]. For patients with
missing individual-level social economic status, we used
the social economic status for the patient’s general prac-
tice. Patient body mass index (BMI) (kg/m2) was grouped
into BMI < 18.5 as underweight, 18.5-25.0 as normal
weight, 25.0-30 as overweight and ≤ 30 as obese. Smoking
status was recorded as current smokers, ex-smokers and
non-smoker in the patient record. Both BMI and smoking
status were taken from data recorded closest to index
date. Therefore, it was assumed that these states had not
changed during the study period. See Additional file 1 for
further methodology details on variable construction.
Statistical analysis
All data were analysed using Stata 14 software (Stata
Corp, Texas). Baseline characteristics among patients
with and without CKD were compared using χ2 tests.
Throughout this study we used unconditional Poisson
regression analysis to investigate the association between
CKD status and TB incidence taking account of cluster-
ing by general practice using random errors. We did not
use matched analysis as we removed prevalent TB cases
so the original matching was not maintained, but
analysis was adjusted for matching factors (age, gender,
calendar year, random effect for general practice). Using
a forward analysis, models were developed with guidance
from the relationships between variables on a conceptual
diagram since not all potential confounders could be ad-
justed for in the final model as there were only 246 TB
cases (Fig. 2) (Additional file 2). Variables were kept in
the model if they changed the point estimate for rate ra-
tio of TB in those with CKD. With the addition of each
variable, we checked for multicollinearity by analysing
changes in standard errors and point estimates. We
assessed the influence of BMI on results and found that
addition of this variable led to an increase in estimates,
whilst addition of diabetes led to attenuation of associ-
ation. Hence, to have a conservative estimate, in the final
model we adjusted for age, gender, ethnicity, IMD, dia-
betes and COPD. We used likelihood ratio methods to
test whether CKD is associated with TB diagnosis after
adjusting for these six factors.
Subgroup analysis
In examining whether there was a dose-response rela-
tionship between CKD (stage 3a, 3b, and 4) and TB inci-
dence, we included CKD stage as a continuous score
variable in the models.
Effect modification
A priori effect modification of the relationship between
CKD and TB by age and ethnicity was explored by using
Fig. 2 Conceptual diagram of associations between chronic kidney disease stages 3–5 and tuberculosis. BMI = body mass index, IMD = index of
multiple deprivation, RA = Rheumatoid arthritis, CKD = chronic kidney disease stages 3–5
Ruzangi et al. BMC Nephrology          (2020) 21:420 Page 4 of 9
likelihood ratio tests. We were concerned that the age
modification was driven by non-whites since age and
ethnicity are closely correlated as a result of past migra-
tion patterns, so we explored the effect modification
with age in whites only. We tested for interaction after
adjusting for gender, IMD and diabetes.
Results
As shown in Fig. 1, among 4,070,806 eligible patients (me-
dian age 39 [IQR 27–56], female 51.2%), 264,628 had
CKD (median age 77 [IQR 71–83], male 38.7%). Of these,
242,349 patients were matched by age, gender, general
practice and cohort entry date to a control without CKD.
Unmatched patients with CKD (n = 22,279) were more
likely to be female and older (median age 88 [IQR 84–92],
female 68.5%). Of the 242,349 matched control patients,
41,151 (17.0%) were later found to have CKD (therefore,
were included in the CKD cohort from that time point
forward and are included in the final CKD cohort of 238,
513). After excluding existing TB cases at index date
(7486 patients), 477,212 patients were left with follow-up
time from almost a month to 10 years (median 3.81 years).
Patients with CKD were more likely to be overweight
with BMI ≥ 25 kg/m2, deprived and ex-smokers compared
to those without CKD. Chronic illnesses were more com-
mon in those with CKD compared to those without CKD
(Table 1). Those who were South Asian, male, under-
weight, most deprived, diabetic or asthmatic were more
frequently diagnosed with TB. Those with COPD, cancer
and rheumatoid arthritis showed increased rates com-
pared to patients without these factors (Additional file 2).
There was strong evidence of within-GP practice cluster-
ing of TB cases (likelihood ratio test for no clustering (θ =
0); P < 0.05) throughout the analysis which was accounted
for by the statistical model.
The overall incidence rate of TB in those without CKD,
and in those with CKD was 9.89 (7.96–12.30) and 14.63
(12.28–17.42) per 100,000-person years, respectively. After
controlling for age, gender, ethnicity, socio-economic sta-
tus, COPD and diabetes, there was strong evidence for a
positive association between CKD status and TB incidence
(adjusted rate ratio [RR] = 1.42, 95%CI 1.09–1.85, p =
0.008) (Table 2). No multicollinearity was observed.
Subgroup analysis
After controlling for age, gender, IMD, ethnicity, COPD
and diabetes, the rate ratio of TB incidence for an in-
crease in one unit in CKD stage amongst those with
CKD stages 3–5 is 1.09 (95%CI 0.82–1.46). There was
no evidence of a trend with CKD severity (p = 0.541).
Effect modification
There was borderline evidence that ethnicity modified
the effect of CKD (p = 0.061) even after adjusting for
age, gender, IMD, COPD and diabetes (Table 3), sug-
gesting that the rate of incident TB associated with CKD
is much higher in those of non-white descent. On crude
analyses there was an interaction with age, however, this
interaction may have been driven by the fact that inci-
dent TB cases occurred in younger people of non-white
ethnicity. Hence, we explored the interaction with age
amongst whites only. Whilst the point estimates suggest
a trend with those of younger age being more suscep-
tible, the confidence intervals are wide, and the result
may be due to chance (Table 4).
Discussion
Key findings and interpretation
In this large study, patients with known CKD were more
likely to be diagnosed with TB than patients without
CKD. There was no evidence that the rate of incident
TB diagnosis varied with severity of kidney function.
The association of CKD with TB may vary by ethnicity
with a stronger association seen in those of non-white
ethnicity.
The results of a positive association between CKD and
incident TB agree with the systematic review reporting
an increased risk of acute community-acquired infec-
tions in adult patients with CKD in high-income coun-
tries [4]. Authors have previously hypothesised that as
kidney function declines the immunity of the host could
be reduced through various mechanisms related to grad-
ual accumulation of uraemic metabolites. It was possible
that the risk of TB associated with CKD only manifested
after a long period, so this study may have underesti-
mated long-term risks. The reported median period of
follow up in this study was 3.81 years. The effect of po-
tential confounders on the effect estimate of CKD on in-
cident TB overall was small and did not appreciably
affect estimates of association. Previous studies on the
risk of active TB in ESKD patients have not adjusted for
socio-economic status, lifestyle factors, or chronic ill-
nesses such as diabetes and COPD [37, 38]. Having
found this association there are a number of open ques-
tions that need to be investigated in future research
using more granular data. It may be that CKD affects
the severity of TB manifestation in those with latent TB.
The association of TB with CKD may be a combination
of increased risk of infection and risk of disease as a
result of decreased immunity in these patients.
The lack of evidence for the variation of TB diagnosis
rate with severity of kidney function may have been
driven by competing risk of death since death was a
marker for end of follow up. A previous study showed
evidence of a graded association between reduced eGFR
and the risk of death, cardiovascular events, and
hospitalization [39]. We did not adjust for competing
risk of death as there was lack of power in groups with
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Table 1 Baseline characteristics of matched patients with and without chronic kidney disease
Patients without CKD N = 238,699 Patients with CKD N = 238,513 p-value
Number (%) Number (%)
Age (years)
< 55 6823 (2.9) 6785 (2.8) 0.990
55–64 23,377 (9.8) 23,278 (9.8)
65–74 70,027 (29.3) 69,963 (29.3)
75–84 100,761 (42.2) 100,733 (42.3)
> =85 37,711 (15.8) 37,754 (15.8)
Gender
Male 93,860 (39.3) 93,824 (39.3) 0.912
Female 144,839 (60.7) 144,689 (60.7)
Ethnicity
White/not-recordeda 233,154 (97.7) 233,179 (97.8)
South Asian 1712 (0.7) 2153 (0.9) < 0.001
Black 1144 (0.5) 1041 (0.4)
Otherb 2689 (1.1) 2140 (0.9)
Index of Multiple Deprivationc
1(least deprived) 55,982 (23.5) 52,223 (21.9)
2 60,777 (25.5) 59,575 (25.0)
3 49,736 (20.8) 49,931 (20.9) < 0.001
4 41,539 (17.4) 43,986 (18.4)
5(most deprived) 30,665 (12.9) 32,798 (13.8)
Smoking status
Non-Smoker 91,030 (38.1) 79,432 (33.3)
Current Smoker 35,834 (15.0) 28,796 (12.1) < 0.001
Ex-Smoker 105,966 (44.4) 129,414 (54.3)
Missing 5869 (2.5) 871 (0.4)
Body mass index (kg/m2)
< 18.5 6469 (2.7) 4454 (1.9)
18.5–25 83,966 (35.2) 68,760 (28.8) < 0.001
25–30 79,336 (33.2) 86,724 (36.4)
≥ 30 39,854 (16.7) 62,385 (26.2)
Missing 29,074 (12.2) 16,190 (6.8)
Chronic physical illnesses
Asthma 27,389 (11.5) 30,595 (12.8) < 0.001
Cancer 46,603 (19.5) 53,450 (22.4) < 0.001
COPD 14,544 (6.1) 17,739 (7.4) < 0.001
Diabetes 23,986 (10.1) 52,141 (21.9) < 0.001
Rheumatoid arthritis 4189 (1.8) 5922 (2.5) < 0.001
CKD chronic kidney disease stages 3–5
COPD chronic obstructive pulmonary disease
awhite/not recorded: 136119 (56.2%) and 140,784 (58.1%) patients with and without CKD stages 3–5, respectively, had missing ethnicity
bother: Mixed, not stated and other ethnicities
cIndex of Multiple Deprivation: 259 (0.1%) and 272 (0.1%) patients with and without CKD stages 3–5 were missing individual data so Index of Multiple Deprivation of
general practice was used
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severe CKD given that there were so few TB cases
overall.
There was borderline evidence that effect of CKD on
TB varied with ethnicity. This interaction has to be con-
firmed in a larger, diverse cohort study as 97.7% of the
present study were white or have no recorded ethnicity
(assumed white). Those who were of non-white ethnicity
experienced a greater CKD effect than whites. This
could be due to higher proportions of latent TB cases
present in non-whites than whites at the start of the co-
hort. The findings were however consistent with a previ-
ous study in South-East London which documented that
approximately 2/3 of cases with TB in the renal unit
were amongst people from non-UK born ethnic minor-
ities [40].
Strengths and limitations
To our knowledge this is the largest cohort study to date
investigating the association between CKD before ESKD
and incidence of TB with individual-level adjustments
for patient demographic and comorbidities. The find-
ing of increased TB risk in people with CKD found
in this study agrees with a similar published study
and reviews looking at different infections in compar-
able study populations, and TB for studies comparing
patients on dialysis to the general population [4, 10,
11]. We used a detailed source of routine data which
is representative of the UK population thereby mini-
mising selection bias [12].
There are a number of limitations pertaining to the
source of the dataset. There was potential of non-
differential misclassification of TB. Currently, latent TB
is tested in those at risk of having TB. There is no
current guideline recommending screening of pre-
dialysis CKD patients for latent TB and hence awareness
of risk of disease so bias would tend towards diluting the
association. We assumed that TB patients would seek
medical care in a setting as the UK where access to
healthcare is free. Diagnosis of TB in secondary care is
highly likely to be communicated to the GP for public
health purposes and due to high risk of side effects from
anti-TB medications as well as the interactions of such
medicines with others prescribed by GP.
Serum creatinine testing in primary care is recom-
mended for people who are considered to be at risk for
CKD [3, 17]. Patients with unmeasured CKD may have
been misclassified as a control, which could underesti-
mate the true CKD-TB association. However, the preva-
lence of CKD identified in CPRD has been shown to be
similar to that estimated in a nationally-representative
survey (Health Survey for England), hence most CKD
patients as defined by reduced eGFR are probably cap-
tured in CPRD [41]. Defining CKD using eGFR from
creatinine measurements is more accurate than using
diagnoses in primary care databases [42].
CKD is a complication of HIV [43]. HIV infection
and/or treatment for the infection or complications may
be associated with development of CKD. HIV infection
is a well-known a risk factor for developing TB [6, 44]. If
HIV was a confounder in this cohort, the effect estimate
calculated may be overestimated. We did not identify
nor adjust for HIV status as this is underreported in GP
records [45]. We did not adjust for BCG vaccination sta-
tus. Infant BCG vaccination is recommended for those
at high risk in the UK. This immunity wanes with time
so may or may not offer little protection from TB for
the majority of this cohort because of their age [46].
We assumed smoking status, IMD, BMI and chronic
illness status taken on/close to index date stayed con-
stant throughout the follow-up period. This would likely
Table 2 Incidence of tuberculosis diagnosis by chronic kidney disease status
No/ person yearsb Ratec (95%CI) Unadjusted rate ratio (95%CI) Adjusted ratea ratio (95%CI)
Patients without CKD (N = 238,699) 92/946306.71 9.89 (7.96–12.30) 1 (reference) 1 (reference)
Patients with CKD (N = 238,513) 154/1068622.53 14.63 (12.28–17.42) 1.48 (1.14–1.91) 1.42 (1.09–1.85)
CI confidence intervals, CKD chronic kidney disease stages 3–5
aadjusted for age, gender, ethnicity, socio-economic status, chronic obstructive pulmonary disease and diabetes
bNo. of patients diagnosed with tuberculosis / total follow up time in person years
cPer 100,000 person-years
Table 3 Association of chronic kidney disease with incident tuberculosis by ethnic group
Group Number of patients Tuberculosis cases/PYa Adjusted rate ratioc (95%CI) P-valueb Test for interaction
p-value
White/not recordedd 466,350 210/1970832.9 1.35 (1.02–1.78) 0.036 0.061
Non-White 10,862 36/44096.337 2.83 (1.32–6.03) 0.007
CKD chronic kidney disease stages 3–5. PY person years
atotal follow up time
bp-value: from Wald test
cfor age, gender, socio-economic status, COPD and diabetes
dwhite/not recorded: 136119(56.2%) and 140,784 (58.1%) patients with and without CKD, respectively, had missing ethnicity
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result in residual confounding from non-differential mis-
classification of these confounders.
There may be a risk of reverse causality especially if
the CKD and TB diagnoses are close together, however,
in this cohort TB of the kidney was rarely recorded.
Similarly, there may be reverse causality between BMI
and TB diagnosis, potentially biasing the true association
between CKD and TB diagnosis.
Conclusion
We find evidence for an increased risk of TB amongst
those with CKD not requiring RRT in a UK General
Practice cohort. This study is beneficial to UK policy
seeking to identify high risk groups in primary care to
test and treat for latent TB to prevent disease– based on
the present study presence of CKD stages 3–5 is associ-
ated with risk of incident TB. These real-world data
highlight useful further research investigating the associ-
ation between CKD and TB in patients of non-white
ethnicity.
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